New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
15:26 EDTSRPTSarepta CEO role in talks with FDA on eteplirsen to be limited, WSJ says
After some of Sarepta Therapeutics' executives worried that CEO Chris Garabedian's involvement in talks with the FDA about its review of the company's DMD drug eteplirsen was counterproductive, the company recently moved to place new limits on his responsibilities to bring them more in-line with other biotech companies of Sarepta's size and maturity, according to The Wall Street Journal, citing people familiar with the matter. Reference Link
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 4, 2014
13:17 EDTSRPTSarepta rises after FDA seeks comment on proposed DMD drug guidance
Subscribe for More Information
12:54 EDTSRPTSarepta strength attributed to circulation of DMD guidance document
Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use